Replies to post #390182 on Innovation Pharmaceuticals Inc (IPIX)

[zandant]

LOL. From the same source who stated as fact that "JNJ will be the BIG player for a BIG Brilacidin deal." How did that work out? .025 a share. Very sad.

[williamssc]

Another avenue is a license deal to further develop B in an intranasal form-
"The Company also plans to seek additional clinical development support from the NIH Antiviral Program for Pandemics (APP). Brilacidin for prophylactic use, including assessing Brilacidin in pre-clinical animal models, is of particular interest due to Brilacidin's blocking and neutralizing antiviral properties and industry investment in developing intranasal-targeted, direct-acting antivirals.

Preliminary Brilacidin formulation work for inhaled delivery has been conducted, with the NIH APP a potential avenue to expand on this work, along with exploring the subcutaneous administration of Brilacidin, which has greater than 70 percent bioavailability via this route of administration."

[MackG]

Agree, runninggirl, Lots of complaints about Leo's salary, but Leo wasn't in it just for a nice salary. I have no doubt that we will see a deal in the coming weeks or months that will make Leo very comfortable in his old age, as well as many of us who have had infinite patience and who have taken advantage of bargain basement prices to lower our cost basis per share.

[sox040713]

The word "transformation" seems to be a favorite among Leo and his shareholders. In 2013 he said:

This is a transformational development for our Company and shareholders; adding the assets of PolyMedix for a tiny fraction of what we believe the company is truly worth,” said Leo Ehrlich, Chief Executive Officer at Cellceutix.

https://www.ipharminc.com/press-release/2016/11/16/cellceutix-acquires-polymedix-assets-from-bankruptcy-court-gains-ownership-of-two-clinical-stage-drugs-multiple-compounds-and-equipment-assets

Maybe Leo was 9 years too early with the "transformation".

The IPIX 2022 TRANSFORMATION is about to happen.